A differentiated botanical ingredient is one whose identity, composition, process and evidence can all be checked
For companies that want a new or better botanical ingredient for supplements, foods, cosmetics or research: the proposed stages and gates, the rules and FDA notification record behind the route, and the documents a customer would receive.
Status. EUTECNIQ is in formation and has not yet developed an ingredient. The pathway below is its proposed working method. Toxicology, clinical studies and commercial manufacturing would be done by qualified partners.
Four kinds of partner bring a material, a market or a technology; each would leave with documents a buyer can test
Text version: partners, rules, stages and documents
Partners
- Ingredient suppliers Hold a raw material or extract and need a specification, a data package and a route to U.S. buyers.
- Brand owners Need an ingredient a competitor cannot match by buying the same plant powder.
- International producers Grow or process a botanical abroad and need identity, safety and regulatory documents for the United States (see global ingredients).
- Technology partners Have a delivery or process technology and need botanical applications, data and a licensing path.
Rules that shape the route
- 21 CFR 190.6 New dietary ingredient notification, 75 days before marketing.
- 21 CFR 170 Food additives and GRAS for food uses.
- 21 CFR 111 Specifications and identity tests at the supplement maker.
- 21 CFR 117 Food CGMP for ingredient-only plants.
- 21 CFR 1, Subpart L Foreign supplier verification by the U.S. importer.
- 21 CFR 101 Labeling and claims for foods and supplements.
- 35 U.S.C. 101 What can be patented; products of nature cannot.
Development stages (proposed)
- 01 Target profile Intended use, market, format, daily amount.
- 02 Source and identity Species, plant part, chemotype; supplier qualified.
- 03 Composition and hazards Markers, contaminants, microbiology.
- 04 Extraction and enrichment Target composition in replicate batches.
- 05 Formulation and delivery Dispersion, dose, taste, stability.
- 06 Stability and specification Limits every lot must meet.
- 07 Safety and regulatory route Safety basis for the intended use.
- 08 Scale-up, IP and transfer Commercial scale; protect what is new.
What the partner would receive
- Target ingredient profile
- Identity file
- Composition profile
- Specification and test methods
- Stability protocol and data
- Regulatory route memo
- Technology-transfer package
Founder experience Founder-reported
The founder reports prior industry work formulating botanical actives in liquid, emulsion, suspension and powder formats, running stability programs and transferring processes to contract manufacturers. That work belongs to his former employers and is not EUTECNIQ's. See the founder profile.
Two extracts sold under one plant name can differ in species, plant part, chemotype, solvent and composition
Text version of the eight pairs
Buyers cannot tell two extracts apart from a label. A differentiated ingredient closes that gap with documents a customer can test.
- Same botanical name≠Same composition
- Extraction yield≠Purity
- Higher marker content≠Higher biological activity
- Similar chromatographic fingerprint≠Equivalent ingredient
- Stability testing≠Validated shelf life
- Increased bioavailability≠Improved efficacy
- Increased bioavailability≠Reduced toxicity
- Laboratory feasibility≠Commercial demonstration
Six kinds of ingredient, each with its own technical risk and an early regulatory question
The regulatory question is listed because it decides which data the later stages must produce.
Show the table (6 rows): Ingredient types with their defining feature, main technical risk and the regulatory quest
| Ingredient type | What defines it | Main technical risk | Regulatory question to answer early |
|---|---|---|---|
| Novel botanical ingredient | A species, plant part or preparation with no U.S. marketing history in the intended category. | Identity methods and safety data start from little or nothing. | Is it a new dietary ingredient, a new food substance, or both? Each has its own route. |
| Standardized extract | An extract controlled to a defined content of one or more marker constituents. | A marker chosen for easy analysis may not track the activity of interest. | Does the process chemically alter the ingredient compared with its marketed form? FDA's view on "chemically altered" is still in draft guidance. |
| Chemotype-specific ingredient | Material from plants of one species whose dominant constituents differ consistently from other plants of that species. | The chemotype has to be confirmed lot by lot at the source. | Does the cited history of use apply to this chemotype? |
| Enriched fraction | A fraction concentrated in one constituent class by separation, such as adsorption resins, liquid-liquid partitioning or membranes. | Enrichment can concentrate unwanted constituents too, and yield falls as purity rises. | Concentration changes intake. Does the existing safety evidence cover the new exposure? |
| Delivery-enabled form | The ingredient built into an emulsion, spray-dried powder, encapsulate or phospholipid complex. | Physical stability in the final product, and evidence for any performance claim. | Do the added excipients have the right status for the category? Is the result a nanomaterial? For nanomaterial forms FDA recommends contacting it before a new dietary ingredient notification. |
| Taste-engineered form | An ingredient modified to reduce bitterness or astringency. | Masking can slow release and change exposure. | Are the masking agents lawful in the intended category? |
Regulatory notes: FDA draft guidance, "Dietary Supplements: New Dietary Ingredient Notifications and Related Issues" (2016 revised draft; Section IV.B still draft as of October 2026); FDA final guidance, "NDI Notifications and Related Issues; Identity and Safety Information About the NDI" (October 19, 2026), Section VIII.
Eight stages, each ending in a written decision
Each stage produces a document a customer can audit; a stage passes only when its gate is met.
Text version: objective, measurements, output, gate and owner for each stage
| Stage | Objective | Key measurements | Output | Decision gate | Who does it |
|---|---|---|---|---|---|
| 01 Target profile | Define the intended use, market, format, daily amount and the claim to be tested. | Literature and regulatory review; specifications of competing ingredients. | Target ingredient profile and a regulatory route hypothesis. | A lawful route exists and the profile is technically plausible. | EUTECNIQ with the customer |
| 02 Source and identity | Confirm species, plant part and chemotype where relevant; qualify the supplier. | Macroscopy and microscopy, HPTLC fingerprint, DNA methods as support, voucher specimen. | Identity file and supplier qualification record. | Identity confirmed by orthogonal methods on representative lots. | EUTECNIQ; herbarium and DNA laboratories as partners |
| 03 Composition and hazards | Know what the material contains and what it must not contain. | LC-MS and HPLC-DAD profiles, marker assays, elemental impurities by ICP-MS, pesticide residues, mycotoxins, microbiology. | Composition profile and hazard screen. | No intrinsic hazard at the intended exposure that processing cannot remove. | EUTECNIQ; contract laboratories until in-house methods exist |
| 04 Extraction and enrichment | Design a process that reaches the target composition every time. | Solvent screening, yield and purity at each step, mass balance, residual solvents. | Process description, laboratory batches and mass balance. | Target composition reached in replicate batches with acceptable yield and solvent residues. | EUTECNIQ |
| 05 Formulation and delivery | Make the ingredient work in its format: dispersion, dose, taste and stability. | Solubility and dispersibility, particle or droplet size, zeta potential, dissolution, sensory panels. | Prototype forms with physical and sensory data. | The prototype meets physical and sensory targets in the intended product. | EUTECNIQ |
| 06 Stability and specification | Set the limits every lot must meet and learn how the ingredient changes over time. | Real-time and accelerated stability: assay, degradation products, physical attributes. | Specification, test methods, stability protocol and interim data. | Pilot lots meet the specification, with no unexplained trend in stability data. | EUTECNIQ |
| 07 Safety and regulatory route | Build the safety basis for the intended use in the intended market. | Exposure estimate, history-of-use evidence, toxicology studies where the gaps require them. | Regulatory route memo; safety dossier or notification draft. | The evidence supports the intended use at the intended exposure. | EUTECNIQ for strategy and dossier; contract research organizations for toxicology; regulatory counsel |
| 08 Scale-up, IP and transfer | Move the process to commercial scale and protect what is new. | Comparability of laboratory, pilot and commercial lots. | Technology-transfer package, invention disclosures, patent filings where justified. | Commercial lots are comparable to development lots; freedom to operate has been reviewed. | Contract manufacturers and patent counsel; EUTECNIQ for comparability |
"EUTECNIQ" means work planned for its own scientists once its laboratory exists; "partner" means qualified external organizations.
A specification turns a botanical into an ingredient that can be bought, tested and released
The skeleton that 21 CFR 111.70(e) requires for supplements serves the other markets too.
Text version of the specification attributes
| Attribute | What it controls | Methods EUTECNIQ proposes |
|---|---|---|
| Identity | The right species, plant part and preparation. | Macroscopy and microscopy; HPTLC or LC fingerprint against reference material. |
| Strength | Content of the defined marker or active constituents. | HPLC with UV, diode-array or mass-spectrometric detection, validated for the matrix. |
| Composition | The pattern of constituent classes, the extraction solvent and any carrier. | Fingerprint similarity, loss on drying, carrier content. |
| Purity | Absence of adulterants and unintended constituents. | Orthogonal fingerprints and targeted adulterant screens. |
| Contaminant limits | Elemental impurities, pesticide residues, mycotoxins, residual solvents and microorganisms. | ICP-MS; LC-MS/MS and GC-MS/MS; headspace GC; culture-based microbiology. |
| Physical attributes | Particle size, bulk density, moisture and dispersibility. | Laser diffraction, bulk and tapped density, loss on drying, dispersion tests. |
A supplement maker must run at least one appropriate identity test on every dietary ingredient before use (21 CFR 111.75(a)(1)(i)). A well-built ingredient specification therefore includes an identity method the customer can repeat in its own laboratory.
When the process changes, comparability data show whether the ingredient changed with it
Scale-up, a new supplier or a new solvent can shift composition.
Text version of the protocol and the guidance
What a comparability protocol compares Proposal
- Chromatographic fingerprints and their similarity.
- Ratios between marker constituents, not only their totals.
- Impurity and contaminant profiles.
- Physical attributes that affect the finished product.
- Early stability trends of the new lots.
Why regulators care
- Draft guidance FDA's 2016 revised draft NDI guidance discusses when a manufacturing change creates a new dietary ingredient. That section is still draft as of October 2026.
- Final guidance FDA's June 2014 guidance on significant manufacturing process changes recommends consulting FDA about such a change to a food substance already on the market, especially when it involves an emerging technology such as nanotechnology.
- Final guidance For botanical drugs, FDA links batch consistency to consistent therapeutic effect through a "totality of the evidence" approach (December 2016).
Sources: FDA draft NDI guidance (docket FDA-2011-D-0376, October 2026 version), Section IV.A; FDA, "Assessing the Effects of Significant Manufacturing Process Changes…" (June 2014, docket FDA-2011-D-0490); FDA, "Botanical Drug Development" (December 2016, Revision 1).
Delivery, stability and taste are engineered from the molecule's own properties
A carrier is chosen after the active's solubility, stability and dose are known, then tested in the final product.
Text version of the four distinctions
Delivery
Solubility is how much dissolves. Dispersibility is how well particles or droplets stay spread through a liquid. They need different fixes.
Microemulsions are thermodynamically stable; nanoemulsions are not, and persist only because breakdown is slow. Amorphous solid dispersions raise apparent solubility, and recrystallization is their main risk.
McClements 2012, Soft Matter 8:1719; Bhujbal et al. 2021, Acta Pharm Sin B 11:2505. More on the delivery and emulsions pages.
Stability
Chemical degradation, such as oxidation or hydrolysis, and physical separation, such as creaming or caking, are different failures with different tests.
Stability testing produces data. A shelf life is a conclusion drawn from data on the final product in its package. Part 111 does not require an expiration date, but FDA says a firm should have data to support any date it puts on a label.
FDA, Small Entity Compliance Guide for 21 CFR Part 111 (December 2010), citing 72 FR 34752 at 34855.
Taste and sensory Proposal
Many polyphenols and alkaloids are bitter or astringent. Masking options include encapsulation, complexation and flavor systems.
Each option would be checked with trained sensory panels and with dissolution testing, because a coating that hides taste can also slow release.
Bioavailability research measures exposure, and exposure alone establishes neither efficacy nor safety
A formulation can improve one step between dose and outcome and leave the others unchanged.
- Dose in the productLabel amount and assay
- ReleaseDisintegration and dissolution tests
- Bioaccessible fractionIn vitro digestion, for example INFOGESTBioaccessibility
- Absorption and first-pass metabolismCell permeability models; metabolism assays
- Systemic exposureHuman pharmacokinetic study: AUC and CmaxBioavailability
- Effect at the targetMechanism and biomarker studies
- Health outcomeRandomized, controlled human trialEfficacy
Text version of the piperine example and the transfer problem
A worked example: piperine and curcumin Peer-reviewed
In a 1998 study, 20 mg of piperine given with 2 g of curcumin raised serum curcumin in healthy volunteers. The authors reported a 2000% increase in bioavailability.
Piperine inhibits glucuronidation. In laboratory studies it also inhibits the human drug transporter P-glycoprotein and the enzyme CYP3A4. The mechanism that raises curcumin exposure could therefore raise exposure to drugs taken at the same time.
Shoba et al. 1998, Planta Med 64:353; Bhardwaj et al. 2002, J Pharmacol Exp Ther 302:645.
Why published numbers rarely transfer
Reported gains for curcumin formulations vary with the product, the comparator, the dose and the analytical method. One review flags hydrolysis of plasma samples, which measures conjugates together with free curcumin, as an inappropriate practice.
For nanomaterial forms, FDA's October 2026 NDI guidance says data on the non-nano version are unlikely to address safety concerns specific to the nanomaterial.
Jamwal 2018, J Integr Med 16:367; Stohs et al. 2020, Molecules 25:1397; FDA final NDI identity and safety guidance (October 19, 2026), Section VIII.
Explanation, details and sources
Why published numbers rarely transfer. Reported gains for curcumin formulations vary with the product, comparator, dose and analytical method; one review flags hydrolysis of plasma samples, which measures conjugates with free curcumin, as an inappropriate practice. For nanomaterial forms, FDA's October 2026 NDI guidance says data on the non-nano version are unlikely to address nanomaterial-specific safety concerns.
Jamwal 2018, J Integr Med 16:367; Stohs et al. 2020, Molecules 25:1397; FDA final NDI identity and safety guidance (October 19, 2026), Section VIII.
Proposal EUTECNIQ would report exposure studies as exposure studies, name the analyte measured (free or total), and not turn a pharmacokinetic result into an efficacy or safety claim. Human studies would run at qualified clinical sites under IRB oversight; see clinical research.
The regulatory route is chosen before the expensive studies, because it decides which studies count
The same extract can need a different safety package in each market. Stage 01 fixes the market; stage 07 builds the evidence that market expects.
Data tables: notifications per year and days to response
| 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Notifications | 2 | 8 | 14 | 19 | 24 | 31 | 20 | 53 | 64 | 43 | 57 | 64 | 73 | 40 | 47 | 53 | 49 | 42 | 33 | 40 | 48 | 60 | 93 | 42 | 33 | 54 | 42 | 33 | 45 | 59 | 71 | 9 |
| 0-30 days | 31-45 days | 46-60 days | 61-75 days | 76-90 days | 91-120 days | >120 days | |
|---|---|---|---|---|---|---|---|
| Notifications | 96 | 61 | 134 | 828 | 127 | 57 | 56 |
Data table: every rule set in the treemap
| Rule set | What it covers | Agency group | eCFR sections | Level |
|---|---|---|---|---|
| 21 CFR Part 111 | Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. CGMP for anyone who makes, packages, labels or holds a dietary supplement, including identity tests of dietary ingredients. | FDA · 21 CFR | 84 | Check |
| 21 CFR Part 117 | Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food. CGMP, hazard analysis and preventive controls for human food, including dietary ingredients. | FDA · 21 CFR | 61 | Applies |
| 21 CFR Part 101 | Food Labeling. Food labels: Supplement Facts (§ 101.36), health claims (§ 101.14) and structure/function statements (§ 101.93). | FDA · 21 CFR | 50 | Check |
| 21 CFR Part 1, Subpart R | Laboratory Accreditation for Analyses of Foods. Certain food tests, such as tests to support admission of an import, must be run by a LAAF-accredited laboratory. | FDA · 21 CFR | 42 | Check |
| 21 CFR Part 58 | Good Laboratory Practice for Nonclinical Laboratory Studies. Good laboratory practice for nonclinical studies supporting the FDA submissions listed in § 58.3; NDINs are not listed. | FDA · 21 CFR | 36 | Check |
| 21 CFR Part 1, Subpart O | Sanitary Transportation of Human and Animal Food. Shippers, loaders, carriers and receivers keep food safe during transport; § 1.900(b) lists exempt operations. | FDA · 21 CFR | 18 | Check |
| 21 CFR Part 1, Subpart H | Registration of Food Facilities. Facilities that make, process, pack or hold food for U.S. consumption register with FDA and renew every two years. | FDA · 21 CFR | 14 | Applies |
| 21 CFR Part 1, Subpart J | Establishment, Maintenance, and Availability of Records. Keep records of the immediate previous source and the immediate subsequent recipient of food. | FDA · 21 CFR | 13 | Applies |
| 21 CFR Part 173, Subpart C | Secondary Direct Food Additives Permitted in Food for Human Consumption. Residue limits for extraction solvents in named foods, such as hexane at 25 ppm in spice oleoresins. | FDA · 21 CFR | 11 | Check |
| 21 CFR Part 7, Subpart C | Enforcement Policy. FDA's recall policy: recalls are voluntary actions, classified by health hazard, with a recall strategy. | FDA · 21 CFR | 10 | Check |
| 21 CFR Part 11 | Electronic Records; Electronic Signatures. Electronic records and signatures that meet FDA record rules must be trustworthy, reliable and equivalent to paper. | FDA · 21 CFR | 10 | Applies |
| 21 CFR Part 190 | Dietary Supplements. A new dietary ingredient needs notification to FDA at least 75 days before marketing, unless the food-supply exception applies. | FDA · 21 CFR | 1 | Check |
| 40 CFR Part 180 | Tolerances and Exemptions for Pesticide Chemical Residues in Food. Tolerances and exemptions for pesticide residues in food; inert-ingredient exemptions are in §§ 180.910–180.960. | EPA · 40 CFR | 755 | Applies |
| 40 CFR Part 261 | Identification and Listing of Hazardous Waste. Which wastes are hazardous: ignitable wastes (§ 261.21) and listed wastes such as spent solvents (§ 261.31). | EPA · 40 CFR | 83 | Check |
| 40 CFR Part 262 | Standards Applicable to Generators of Hazardous Waste. Duties of hazardous-waste generators, scaled by generator category. | EPA · 40 CFR | 66 | Check |
| 29 CFR 1910.1200 | Hazard communication.. Hazard communication: hazard classification, labels, safety data sheets and worker training. | OSHA · 29 CFR | 1 | Applies |
| 29 CFR 1910.106 | Flammable liquids.. Storage and handling of flammable liquids, such as ethanol and hexane used in extraction. | OSHA · 29 CFR | 1 | Applies |
| 29 CFR 1910.119 | Process safety management of highly hazardous chemicals.. Process safety management, triggered for example by 10,000 lb of a flammable liquid with flash point below 100 °F in one process. | OSHA · 29 CFR | 1 | Check |
| 29 CFR 1910.132 | General requirements.. Workplace hazard assessment and personal protective equipment. | OSHA · 29 CFR | 1 | Applies |
| 29 CFR 1910.134 | Respiratory protection.. Respiratory protection programs where respirators are needed. | OSHA · 29 CFR | 1 | Check |
| 29 CFR 1910.147 | The control of hazardous energy (lockout/tagout).. Lockout/tagout of hazardous energy during servicing and maintenance of machines. | OSHA · 29 CFR | 1 | Check |
| 29 CFR 1910.307 | Hazardous (classified) locations.. Electrical equipment in hazardous (classified) locations, such as rooms with flammable vapors. | OSHA · 29 CFR | 1 | Check |
| 29 CFR 1910.1000 | Air contaminants.. Permissible exposure limits for air contaminants, such as solvent vapors. | OSHA · 29 CFR | 1 | Check |
| 29 CFR 1910.1450 | Occupational exposure to hazardous chemicals in laboratories.. Chemical hygiene plan and exposure controls for laboratory use of hazardous chemicals. | OSHA · 29 CFR | 1 | Applies |
| Total | 24 rule sets; 9 apply, the rest apply only in the circumstances they name | 1263 | 857 in rules that apply |
Show the table (5 rows): First regulatory question and route for each target market.
| Target market | First question | Usual route |
|---|---|---|
| Dietary supplement | Is it a new dietary ingredient, and does the food-supply exception apply? | New dietary ingredient notification, or records showing marketing before October 15, 1994. |
| Food or beverage | Is it a food additive, or generally recognized as safe for this use? | GRAS conclusion and notice, or a food additive petition. |
| Cosmetic | Is every claim a cosmetic claim, and is safety on skin substantiated? | Safety substantiation, facility registration and product listing. |
| Drug research | Is there a sponsor prepared to file an IND? | Partner-led drug development. |
| Outside the United States | Which national category fits, and who must hold the authorization? | International market access. |
Protectable inventions usually lie in the process and the formulation, rarely in the plant
A naturally occurring substance is not patent-eligible merely because it has been isolated.
Text version of candidate inventions and limits
Candidate inventions in a development program Proposal
- Extraction and enrichment sequences that give an unexpected composition or yield.
- Delivery-system compositions and the methods of making them.
- Stabilization and taste-masking methods.
- Analytical methods that confirm identity or chemotype.
- Process know-how kept as a trade secret where disclosure would not pay.
The limits Law and case law
The Supreme Court held that "a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated" (2013). USPTO examiners ask whether a nature-based product has markedly different characteristics from its natural counterpart.
Patentability is decided case by case. EUTECNIQ holds no patents. Ownership of inventions made in a program would be fixed in the written agreement; see commercialization and licensing.
35 U.S.C. 101; Association for Molecular Pathology v. Myriad Genetics, Inc., No. 12-398 (U.S. June 13, 2013); USPTO, MPEP § 2106.04(c).
Three ways to work together, sized to the question
Text version of the three models
Feasibility study
For an early question about one material.
- Literature and regulatory screen
- Identity and composition snapshot
- Go or no-go memo with next steps
Development program
For a defined ingredient target.
- Written gate at the end of each stage
- Specification, process description, stability protocol
- Regulatory route memo and safety plan; partner studies contracted with the customer's approval
Co-development
For an ingredient or technology both parties will own or license.
- Agreed ownership, cost sharing and licensing terms
- Joint stage gates
- Scale-up and technology transfer
Discuss an ingredient program
Tell us about the material, the target market and the question you need answered first. The reply would propose a scope, starting with a feasibility study where the answer is not yet clear.